​

AstraZeneca (AZN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AZN Stock Forecast

AstraZeneca (AZN) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $186.67, with a high of $216.00 and a low of $158.00. This represents a 8.85% increase from the last price of $171.49.

$155 $168 $181 $194 $207 $220 High: $216 Avg: $186.67 Low: $158 Last Closed Price: $171.49

AZN Stock Rating

AstraZeneca stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 1 Strong Buy (2.44%), 19 Buy (46.34%), 15 Hold (36.59%), 6 Sell (14.63%), and 0 Strong Sell (0.00%).

Buy
Total 41 6 15 19 1 Strong Sell Sell Hold Buy Strong Buy

AZN Price Target Upside V Benchmarks

TypeNameUpside
StockAstraZeneca8.85%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks4.82%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$211.00
Last Closing Price$171.49$171.49$171.49
Upside/Downside--23.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26371--11
Sep, 26371--11
Aug, 26262--10
Jul, 26271--10
Jun, 26271--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025HSBC$108.00$89.8220.24%-37.02%
Dec 03, 2025Morgan Stanley$103.00$90.1714.23%-39.94%
Jul 09, 2025Luisa HectorBerenberg Bank$97.00$70.8236.97%-43.44%
Nov 13, 2024Etzer DaroutBMO Capital$88.00$81.198.39%-48.69%
Sep 11, 2024Etzer DaroutBMO Capital$89.00$79.9411.33%-48.10%
May 30, 2024John EadeArgus Research$85.00$76.8410.62%-50.43%
May 28, 2024Etzer DaroutBMO Capital$82.00$76.746.85%-52.18%
Jul 12, 2023Andrew BerensLeerink Partners$79.00$64.8621.80%-53.93%
Jan 05, 2023BMO Capital$82.00$69.5017.99%-52.18%
Nov 11, 2022Leerink Partners$78.00$65.0919.83%-54.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026NordeaSellBuyupgrade
Oct 06, 2026CitigroupBuyBuyhold
Sep 15, 2026Deutsche BankSellHoldupgrade
Sep 08, 2026RBC CapitalOutperforminitialise
Aug 23, 2026CICCOutperforminitialise
Jul 13, 2026HSBCBuyHolddowngrade
Jul 09, 2026Goldman SachsBuyBuyupgrade
Apr 30, 2026JefferiesBuyBuyhold
Apr 08, 2026Morgan StanleyOverweightOverweighthold
Mar 18, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$0.04$1.06$1.91$1.14-----
Avg Forecast$2.59$3.36$4.16$8.21$9.17$10.28$11.57$13.00$14.51
High Forecast$2.67$3.46$4.33$8.51$9.39$10.68$13.15$14.20$15.11
Low Forecast$2.43$3.14$3.94$8.09$8.95$10.16$8.60$11.80$13.74
Surprise %-98.46%-68.45%-54.09%-86.11%-----

Revenue Forecast

$30B $40B $50B $60B $70B $80B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$37.42B$44.35B$45.81B$54.07B-----
Avg Forecast$36.41B$44.44B$49.13B$53.12B$58.66B$62.32B$66.45B$70.46B$75.15B
High Forecast$37.29B$44.46B$50.70B$53.49B$59.18B$63.31B$66.73B$70.81B$77.54B
Low Forecast$34.62B$44.42B$47.13B$52.59B$57.43B$61.40B$66.17B$70.11B$72.09B
Surprise %2.76%-0.20%-6.76%1.80%-----

Net Income Forecast

$-5B $6B $17B $28B $39B $50B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$112.00M$3.29B$5.96B$7.04B-----
Avg Forecast$-238.15M$6.16B$12.92B$25.95B$28.66B$32.58B$34.00B$40.64B$45.35B
High Forecast$595.60M$9.25B$13.53B$26.60B$29.35B$33.39B$41.12B$44.38B$47.23B
Low Forecast$-1.07B$3.07B$12.31B$25.29B$27.97B$31.76B$26.87B$36.90B$42.96B
Surprise %-147.03%-46.65%-53.91%-72.89%-----

AZN Forecast FAQ

Is AstraZeneca stock a buy?

AstraZeneca stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 15 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that AstraZeneca is a favorable investment for most analysts.

What is AstraZeneca's price target?

AstraZeneca's price target, set by 41 Wall Street analysts, averages $186.67 over the next 12 months. The price target range spans from $158 at the low end to $216 at the high end, suggesting a potential 8.85% change from the previous closing price of $171.49.

How does AstraZeneca stock forecast compare to its benchmarks?

AstraZeneca's stock forecast shows a 8.85% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (4.82%).

What is the breakdown of analyst ratings for AstraZeneca over the past three months?

  • October 2026: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is AstraZeneca’s EPS forecast?

AstraZeneca's average annual EPS forecast for its fiscal year ending in December 2025 is $9.17, marking a 704.39% increase from the reported $1.14 in 2024. Estimates for the following years are $10.28 in 2026, $11.57 in 2027, $13 in 2028, and $14.51 in 2029.

What is AstraZeneca’s revenue forecast?

AstraZeneca's average annual revenue forecast for its fiscal year ending in December 2025 is $58.66B, reflecting a 8.48% increase from the reported $54.07B in 2024. The forecast for 2026 is $62.32B, followed by $66.45B for 2027, $70.46B for 2028, and $75.15B for 2029.

What is AstraZeneca’s net income forecast?

AstraZeneca's net income forecast for the fiscal year ending in December 2025 stands at $28.66B, representing an 307.39% increase from the reported $7.04B in 2024. Projections indicate $32.58B in 2026, $34B in 2027, $40.64B in 2028, and $45.35B in 2029.